EGFR and VEGFR as potential target for biological therapies in HCC cells

Gianluigi Giannelli, Concetta Sgarra, Letizia Porcelli, Amalia Azzariti, Salvatore Antonaci, Angelo Paradiso

Research output: Contribution to journalArticlepeer-review


Hepatocellular carcinoma (HCC) is a highly malignant cancer with poor prognosis. Inhibitors of EGFR and VEGFR for HCC treatment are currently under investigation. Gefitinib and vandetanib inhibit migration of HCC cells on Laminin-5 and Fibronectin, and invasion through matrigel. Both drugs inhibit p-EGFR after short time, while their efficacy on p-Erk1/2 and p-Akt is progressive and stable over time. PI3K/Akt and MEK/Erk1/2 inhibitors, inhibit migration and invasion as well as inducing de-phosphorylation of downstream effectors. Finally, both inhibitors, vandetanib and gefitinib down-regulated the secretion of matrix metalloproteases MMP-2 and MMP-9. All these biological effects seem to depend on the activity of gefitinib and vandetanib blocking activity towards p-EGFR mediated pathways.

Original languageEnglish
Pages (from-to)257-264
Number of pages8
JournalCancer Letters
Issue number2
Publication statusPublished - Apr 18 2008


  • Cell signalling vandetanib
  • EGFR
  • Gefitinib
  • HCC
  • Matrix metalloproteases
  • TK inhibitors

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Biology
  • Oncology


Dive into the research topics of 'EGFR and VEGFR as potential target for biological therapies in HCC cells'. Together they form a unique fingerprint.

Cite this